NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
April 17, 2007 • Volume 4 / Number 15 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
Antiangiogenic Agent Shows Promise against Glioblastoma

Director's Update
Supporting Quality Research Remains NCI's Top Priority

Cancer Research Highlights
Gleevec Protects Against Recurrence of Gastrointestinal Tumors

Palliative Radiation Extends Survival for Elderly Patients with Glioblastoma

Hispanic Breast Cancer Differences Persist with Equal Access to Care

Age, Race, and Income Level Associated with Undertreatment of Ovarian Cancer

CCR Grand Rounds

University of Michigan Hosts Town Hall Meeting: Stopping Cancer Before It Starts

Spotlight
Mammogram Study Evaluates Computer-Aided Detection

Funding Opportunities

Featured Clinical Trial
Reactivating Tumor Suppressor Genes

AACR Annual Meeting Coverage
HPV Vaccines Demonstrate Long-Term Protection

Engineered Virus Delivers Killer Protein to Prostate Cancer Cells

Risk of Colon Cancer in African Americans Linked to Genetic Variants

Notes
NCI Scientists and Advisor Receive AACR Awards

Collins to Give Kaplan Lecture at Harvard

Free Telephone Workshop for Cancer Survivors

NCI 70th Anniversary: If Memory Serves...

A Closer Look
Breast Cancer in the News

Bulletin Archive

About the Bulletin

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Featured Article

Antiangiogenic Agent Shows Promise against Glioblastoma

An experimental antiangiogenesis drug may improve the treatment of the most common and deadly type of adult brain cancer, researchers from Massachusetts General Hospital and Harvard Medical School reported this week at the American Association for Cancer Research (AACR) annual meeting in Los Angeles.

The promising clinical results were buttressed by imaging and biomarker analyses that support a theory that the value of antiangiogenic agents may not be limited to halting the development of blood vessels that feed tumors, but that the drugs also can "normalize" them to the point where the delivery of standard treatments to the tumor may be improved.  Read more  



Director's Update

Supporting Quality Research Remains NCI's Top Priority

I had the opportunity once again to provide the NCI Director's update at the American Association for Cancer Research meeting in Los Angeles.

It was an honor as a long-standing member of the organization to participate in the annual meeting as the NCI Director. I am pleased to see the significant growth and outstanding progress made by our organization.

During my talk, I took the opportunity to discuss some areas of research that I find particularly intriguing - including cancer stem cells and potential diagnostic applications of chromosome location mapping, for example - and to address some of the issues that are part of the conversation in the scientific community about the NCI budget and its potential impact on the future of cancer research.  Read more  


The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.

NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.

Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov